# BPC-157 TB-500: The Wolverine Peptide Blend, Read From the Literature > BPC-157 TB-500 is the two-peptide Wolverine blend — BPC-157 supplies a cytoprotective, pro-angiogenic signal; TB-500 supplies G-actin sequestration. A research console on what each constituent's literature establishes, with no controlled combination trial on record. BPC-157 supplies a local cytoprotective, pro-angiogenic signal; TB-500 supplies an intracellular G-actin-sequestration signal. This is a research console reading each constituent's published literature, cited to source — and marking, plainly, where the blend itself has no human data. ## What the Wolverine peptide blend is BPC-157 TB-500 — marketed as the "Wolverine" peptide blend — is not one molecule. It is a research-community pairing of two distinct synthetic peptides discussed together as a tissue-repair stack. BPC-157 is a 15-amino-acid pentadecapeptide (sequence `GEPPPGKPADDAGLV`, ~1419.5 Da) derived from a partial sequence of a protein found in human gastric juice [1]. TB-500 is a synthetic N-acetylated heptapeptide, `Ac-LKKTETQ` (~889 Da), corresponding to residues 17-23 — the actin-binding motif — of the 43-residue intracellular protein Thymosin Beta-4 [5][6]. The blend has no single molecular weight, no CAS number, and no standardized composition. Commercial "Wolverine" vials are commonly labeled with a combined per-vial mass — a `10 mg + 10 mg` BPC-157:TB-500 pairing, for instance — but no ratio is clinically validated, and no peer-reviewed combination dose-finding study exists [9]. As a [wolverine peptide](/#what-it-is) term, the name is also conflated with the X-Men character in search data; here it refers strictly to this two-peptide construct. This site occupies the "doctor" position the domain name implies in one narrow sense only: it reads the regulatory and access record as carefully as it reads the science. It is an editorial console, not a clinic. The clearest single fact about the pairing is the absence at its center — two mechanisms theorized to converge, and not one trial that tested the convergence. ## BPC 157 TB 500: blend identity at a glance BPC 157 TB 500 reduces to two readouts. BPC-157 is the cytoprotective, pro-angiogenic channel: it up-regulates VEGFR2 with downstream Akt-eNOS signaling and modulates the nitric-oxide system [2]. TB-500 is the cytoskeletal channel: its `LKKTETQ` helix binds monomeric G-actin 1:1, regulating the actin dynamics that drive cell migration [3]. The two channels are largely non-overlapping. BPC-157 acts at the cell surface and in the extracellular repair environment; TB-500 acts intracellularly on the actin pool. That separation is the whole basis of the "synergy" idea — complementary, not redundant, mechanisms. It is also why the idea stays theoretical: complementarity on a mechanism diagram is not a measured combined effect [4]. ## BPC-157 and TB-500: the two peptides a clinician would distinguish BPC-157 and TB-500 differ in structure, size, and mechanism, and a careful reader keeps them apart. BPC-157 is a 15-mer derived from a gastric-juice protein; its characterized role is a local angiogenic and cytoprotective signal acting through VEGFR2 up-regulation and internalization with downstream Akt-eNOS activation [2]. In a transected rat Achilles tendon model it accelerated healing across biomechanical, functional, microscopic, and macroscopic measures [1]. TB-500 is a 7-mer fragment of Thymosin Beta-4. Crystallography of a thymosin-beta-4–actin complex resolved at 2 Å established that the parent peptide forms a 1:1 complex with G-actin and sequesters the monomer by capping both ends, preventing polymerization — the structural basis for the fragment's actin-binding mechanism [3]. One identity caveat runs through everything written about TB-500: the overwhelming majority of efficacy data attributed to it were generated with full-length Thymosin Beta-4 (~4963 Da), not the marketed 7-mer [4]. Read more on [how BPC-157 and TB-500 differ in mechanism](/research). The per-constituent literature is mature on mechanism and entirely preclinical on efficacy. The cross-cutting question — what the two do together in a person — has no answer in the published record. ## BPC-157 TB-500 stack: why it is a research-community label, not a clinical regimen The BPC-157 TB-500 "stack" is a community label, not an approved product or a validated regimen. A 2025 systematic review of BPC-157 in orthopaedic sports medicine screened 36 studies — 35 preclinical, one human — and makes no mention of TB-500 or any combination use [7]. There is no peer-reviewed study that defines a synergy ratio, dose, or endpoint for the two given together [4]. The practical consequence sits on every section of this site: each finding belongs to one constituent, read against that constituent's own studies. The blend-level claim — that the pairing heals injuries faster than either peptide alone — has no human data behind it. That is the honest frame for [the combination rationale and the unproven synergy claim](/research), and the reason the converging "repair signal" stays unlit on the readout above. ## Where the access and regulatory record stands Neither constituent is an FDA-approved drug, and the blend has no approved therapeutic indication anywhere. Both BPC-157 and "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" currently sit in FDA's 503A Category 2 — bulk drug substances FDA has identified as potentially presenting significant safety risks — effective with the September 29, 2023 update to FDA's nominated-substances list [10]. Both are also prohibited in sport by the World Anti-Doping Agency. There is forward motion worth noting honestly: an FDA Pharmacy Compounding Advisory Committee meeting is scheduled for July 23-24, 2026 to discuss BPC-157 and TB-500 as candidates for the Section 503A bulks list — a scheduled evaluation, not a decision [12]. The full record, including how lawful compounded access works, sits on the [Wolverine legal status and FDA 503A compounding access](/legal-status) page. Quantitative findings are detailed on [BPC-157 TB-500 tendon and ligament repair research](/tendon-repair), and dose context on [BPC-157 TB-500 dosage in the research literature](/dosage). --- Two constituent channels read off one console — BPC-157 traced to its studies and TB-500 to its own, the repair-signal node where they converge left dark because no combination trial exists, and the FDA 503A and WADA marks posted before anything else; no clinic behind the readout and nothing here dispensed.